Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic ...

Tango Therapeutics has dosed the first subject in the Phase I/II trial assessing TNG462 in combination with Revolution ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

Clinical-stage oncology company Revolution Medicines and fellow USA-based Summit Therapeutics have entered into a clinical ...

Revolution Medicines has partnered Royalty Pharma for $2bn in flexible funding to support the independent worldwide ...

Royalty Pharma will pay up to $2 billion to Revolution Medicines to support the development and sales of an experimental drug ...

Redwood City, Calif.-based Revolution Medicines is a late-stage clinical oncology company whose clinical-stage inhibitors include daraxonrasib, zoldonrasib, and elironrasib. Summit is a Miami-based ...

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung ...

Revolution Medicines, Inc. (RVMD) and Summit Therapeutics, Inc. (SMMT) have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of ...

BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines ...